Prosecution Insights
Last updated: April 19, 2026
Application No. 18/200,843

SYSTEMS AND METHODS FOR GENERATING AN IMMUNE PROTOCOL FOR IDENTIFYING AND REVERSING IMMUNE DISEASE

Final Rejection §101§112§DP
Filed
May 23, 2023
Examiner
HAMILTON, MATTHEW L
Art Unit
3682
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
Kpn Innovations LLC
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
3y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allow Rate
271 granted / 508 resolved
+1.3% vs TC avg
Strong +62% interview lift
Without
With
+61.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
30 currently pending
Career history
538
Total Applications
across all art units

Statute-Specific Performance

§101
30.0%
-10.0% vs TC avg
§103
33.2%
-6.8% vs TC avg
§102
10.8%
-29.2% vs TC avg
§112
21.7%
-18.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 508 resolved cases

Office Action

§101 §112 §DP
DETAILED ACTION Response to Amendment This action is in response to the amendment filed on November 12, 2025. Claims 1 and 11 have been amended. Claims 1-20 have been examined and are currently pending. Examiner’s note: The examiner reached out to the applicant’s representative, Tyler Anne Giglio several times and was not able to connect to facilitate moving the case forward. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 1 and 11 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Independent claims 1 and 11 recite the limitation, “…determining a threshold level of the nutritional input that indicates a shift on the immune profile;” which is not supported by the applicant’s specification. The applicant’s specification discloses, “…In such an example, immune machine-learning model 136 may determine the effect of nutritional input 132 on PPAR expression and determine at what threshold level of PPAR the immune category 120 shifts. Achieving a shift may include eliminating some nutritional elements from nutritional input 132. Those nutritional elements may be identified in elimination plan 128.” in paragraph 0050 of the applicant’s originally-filed specification. Paragraph 0050 discloses the determining the threshold level of PPAR in which the immune category shifts. It appears that if the limitation was amended to recite, “…determining a threshold level of the nutritional input that indicates a shift on the immune [category] of the biomarker;” it would address the rejection. Additionally, it would be helpful to highlight the differences between the terms, “immune category” and “immune profile” in the independent claims. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: calculating, using the generated immune machine-learning model, an effect of the nutritional input on the immune profile, wherein calculating the effect of the nutritional input further comprises determining a threshold level of the nutritional input that indicates a shift on the immune profile; Response to Arguments Objections to claims 1 and 11 have been withdrawn. Claims 1-20 rejected on the ground of nonstatutory double patenting as being unpatentable have been withdrawn. Claims 1-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW L HAMILTON whose telephone number is (571)270-1837. The examiner can normally be reached Monday-Thursday 9:30-5:30 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fonya Long can be reached at (571)270-5096. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW L HAMILTON/Primary Examiner, Art Unit 3682
Read full office action

Prosecution Timeline

May 23, 2023
Application Filed
Jun 10, 2025
Non-Final Rejection — §101, §112, §DP
Nov 12, 2025
Response Filed
Mar 03, 2026
Final Rejection — §101, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12603184
Systems and Methods for Continuous Cancer Treatment and Prognostics
2y 5m to grant Granted Apr 14, 2026
Patent 12597510
TECHNOLOGIES FOR MEDICAL DEVICE USAGE TRACKING AND ANALYSIS
2y 5m to grant Granted Apr 07, 2026
Patent 12573500
ASSESSING OPERATOR BEHAVIOR DURING A MEDICAL PROCEDURE
2y 5m to grant Granted Mar 10, 2026
Patent 12562281
PREDICTIVE RISK ASSESSMENT IN PATIENT AND HEALTH MODELING
2y 5m to grant Granted Feb 24, 2026
Patent 12562282
PREDICTIVE RISK ASSESSMENT IN PATIENT AND HEALTH MODELING
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
99%
With Interview (+61.8%)
3y 11m
Median Time to Grant
Moderate
PTA Risk
Based on 508 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month